Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors

Vaccine

Volumn 33, Issue 5, 2015, Pages 734-741

  Chit, Ayman ^a,b   Roiz, Julie ^c   Briquet, Benjamin ^c   Greenberg, David P ^d,e  

^a Sanofi Pasteur   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CREATIV CEUTICAL   (France)

^d SANOFI PASTEUR   (France)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Economics; Elderly; Influenza

Indexed keywords

INFLUENZA VACCINE;

AGED; ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFLUENZA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; IMMUNOLOGY; INCIDENCE; INFLUENZA, HUMAN; MALE; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84921286644     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.079     Document Type: Article

References (54)

1. Zhou H., Thompson W.W., Viboud C.G., Ringholz C.M., Cheng P.Y., Steiner C., et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012, 54(May (10)):1427-1436.
2. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR: Morb Mortal Wkly Rep 2010, 27 August (59)(33):1057-1062.
3. Reber A.J., Chirkova T., Kim J.H., Cao W., Biber R., Shay D.K., et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 2012, 3(February (1)):68-90.
4. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012, 8(January (1)):81-88.
5. Skowronski D.M., Masaro C., Kwindt T.L., Mak A., Petric M., Li Y., et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007, 25(12 April (15)):2842-2851.
6. Beran J., Wertzova V., Honegr K., Kaliskova E., Havlickova M., Havlik J., et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009, 9:2.
7. Skowronski D.M., De S.G., Dickinson J., Petric M., Mak A., Fonseca K., et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009, 199(15 January (2)):168-179.
8. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Izu A., Groth N., et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51(1 November (9)):997-1004.
9. Belongia E.A., Kieke B.A., Donahue J.G., Coleman L.A., Irving S.A., Meece J.K., et al. Influenza vaccine effectiveness in Wisconsin during the 2007-2008 season: comparison of interim and final results. Vaccine 2011, 29(2 September (38)):6558-6563.
10. Heinonen S., Silvennoinen H., Lehtinen P., Vainionpaa R., Ziegler T., Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011, 11(January 1):23-29.
11. Janjua N.Z., Skowronski D.M., De S.G., Dickinson J., Crowcroft N.S., Taylor M., et al. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis 2012, 205(15 June (12)):1858-1868.
12. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(2 March (11)):1993-1998.
13. Lee B.Y., Bartsch S.M., Willig A.M. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012, 30(14 December (52)):7443-7446.
14. Beyer W.E., McElhaney J., Smith D.J., Monto A.S., Nguyen-Van-Tam J.S., Osterhaus A.D. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013, 31(5 December (50)):6030-6033.
15. DiazGranados C.A., Denis M., Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012, 31(17 December (1)):49-57.
16. Tricco A.C., Chit A., Soobiah C., Hallett D., Meier G., Chen M.H., et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 2013, 11:153.
17. Lieu T., Meltzer M., Messonnier M.L. Guidance for health economics studies presented to the Advisory Committee on Immunization Practices 2008, US Center for Disease Control and Prevention.
18. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C. Cost-effectiveness in health and medicine 1996, Oxford University Press.
19. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., van R.L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14(June (2)):171-189.
20. McNeil S, Ambrose A, Andrew A, Boivin G, Bowie W, Chit A, et al. Strain specific influenza burden of disease among hospitalized Canadian adults during the 2011/12 season: a Public Health Agency of Canada/Canadian Institutes of Health Research (PCIRN) Serious Outcomes Surveillance Network Study; 2013.
21. Puig-Barberà J, Lopez-Labrador X, Diez-Domingo J, Ruiz-Garcia M, Buigues-Vila A, Barrenengoa-Sanudo J, et al. Influenza vaccine effectiveness, by age group and strain, at preventing laboratory-confirmed influenza admissions in adults 18 years of age or older targeted for influenza vaccination during the 2012-2013 influenza season: a test-negative study; 2013.
22. Pitman R., Fisman D., Zaric G.S., Postma M., Kretzschmar M., Edmunds J., et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 5. Value Health 2012, 15(September (6)):828-834.
23. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005, 23(Suppl. 1):S10-S25.
24. Kostova D., Reed C., Finelli L., et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLOS ONE 2013, 8(6):e66312.
25. Estimated influenza illnesses and hospitalizations averted by influenza vaccination - United States, 2012-13 influenza season. MMWR: Morb Mortal Wkly Rep 2013, 62(13 December (49)):997-1000.
26. United States Census Bureau Age and sex composition in the United States 2012, [accessed 23.12.13]. http://www.census%20gov/population/age/data/2012comp%20html.
27. OECD.Stat. 2013. 10-4-2013. http://stats.oecd.org/Index.aspx?queryname=430%26querytype=view.
28. Mullooly J.P., Bridges C.B., Thompson W.W., Chen J., Weintraub E., Jackson L.A., et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007, 25(15 January (5)):846-855.
29. CDC Self-reported influenza vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status 2013, US Center for Disease Control and Prevention.
30. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272(7 December (21)):1661-1665.
31. Edmondson W.P., Rothenberg R., White P.W., Gwaltney J.M. A comparison of subcutaneous, nasal, and combined influenza vaccination. II. Protection against natural challenge. Am J Epidemiol 1971, 93(June (6)):480-486.
32. Rudenko L.G., Arden N.H., Grigorieva E., Naychin A., Rekstin A., Klimov A.I., et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000, 19(15 September (2-3)):308-318.
33. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(28 June (27)):5086-5096.
34. Schanzer D.L., Langley J.M., Tam T.W. Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada. Vaccine 2008, 26(26 August (36)):4697-4703.
35. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(8 January (2)):179-186.
36. Lawrence W.F., Fleishman J.A. Predicting EuroQoL EQ-5D preference scores from the SF-12 health survey in a nationally representative sample. Med Decis Making 2004, 24(March (2)):160-169.
37. Rothberg M.B., Bellantonio S., Rose D.N. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003, 139(5 Pt 1):321-329.
38. Cooper N.J., Sutton A.J., Abrams K.R., Wailoo A., Turner D., Nicholson K.G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003, 326(7 June (7401)):1235.
39. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(15 September (11)):1333-1340.
40. CMS.gov Physician fee schedule 2013, Centers for Medicare and Meidcaid Services.
41. CMS.gov Clinical Laboratory fee schedule 2013, Centers for Medicare and Meidcaid Services.
42. Lee B.Y., Ercius A.K., Smith K.J. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine 2009, 27(6 April (16)):2251-2257.
43. HCUP.net Healthcare cost and utilization project 2013, US Centeres of Health and Human Services.
44. McNeil S, Ambrose A, Andrew A, Boivin G, Bowie W, Chit A, et al. Effectiveness of 2011/12 seasonal influenza vaccines in the prevention of influenza-related hospitalization in Canadian adults: a Public Health Agency of Canada/Canadian Institutes of Health Research (PCIRN) Serious Outcomes Surveillance Network Study; 2013.
45. ACIP recommendation on herpes zoster vaccine. [accessed 20.02.14]. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm?s_cid=rr5705a1_e.
46. Acosta A. Cost-effectiveness of Tdap substitution for Td in prevention of pertussis in adults 65 years and older. Presented to the Advisory Committee on Immunization Practices (ACIP), February 22, 2012 2012.
47. Krishnarajah G. Cost-effectiveness analysis of Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) among individuals ≥65 years of age in prevention of pertussis. Presented to the Advisory Committee on Immunization Practices (ACIP) 2012.
48. Maciosek M.V., Coffield A.B., Edwards N.M., Flottemesch T.J., Goodman M.J., Solberg L.I. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 2006, 31(1):52-61.
49. DiazGranados C.A., Dunning A.J., Kimmel M., Kirby D., Treanor J., Collins A., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014, 371:635-645. 10.1056/NEJMoa1315727.
50. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J., Randomized Double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
51. Meeting of the Advisory Committee on Immunization Practices (ACIP) additional meetings on use of pneumococcal vaccines in adults; 2014. [accessed 19.08.14]. http://www.cdc.gov/vaccines/acip/meetings/downloads/agenda-archive/agenda-2014-08.pdf.
52. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., Weissert W.G. Willingness to pay for a Quality-Adjusted Life Year: In Search of a Standard. Med Decis Making 2000, 20(3):332-342.
53. Viscusi W.K., Aldy J.E. The value of a statistical life: A critical review of market estimate throughout the world. J risk uncertainty 2003, 27(1):5-76.
54. Braithwaite R.S., Meltzer D.O., King J.T., Leslie D., Roberts M.S. What does the value of modern medicine say about the $50,000 per quality -adjusted life-year decision rule?. Med Care 2008, 46(4):349-355.